Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915483 | 1.00 | MEN1 (0.51) | MEN1KMT2AMAPTNPSR1HPGD | |
| SCHEMBL77732 | 0.88 | MEN1 (0.63) | MEN1KMT2AMAPTNPSR1HPGD | |
| SCHEMBL7380055 | 0.85 | MEN1 (0.50) | MEN1KMT2AMAPTNPSR1HPGD | |
| SCHEMBL7380054 | 0.85 | MEN1 (0.50) | MEN1KMT2AMAPTNPSR1HPGD | |
| SCHEMBL3181449 | 0.84 | MEN1 (0.53) | MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL5101671 | 0.84 | MEN1 (0.53) | MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL3181455 | 0.84 | MEN1 (0.53) | MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL1634878 | 0.83 | MEN1 (0.79) | MEN1KMT2AMAPTNPSR1HPGD | |
| SCHEMBL1633388 | 0.83 | MEN1 (0.79) | MEN1KMT2AMAPTNPSR1HPGD | |
| SCHEMBL2856643 | 0.82 | HTT (0.56) | MEN1KMT2AMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562052-B2 | Bicyclicpyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20150368256-A1 | NEW BICYCLICPYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-24 | — | — | US | disclosed |
| EP-2245008-B1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | CHONG KUN DANG PHARM CORP (KR) | 2013-02-20 | — | — | EP | disclosed |
| US-8178697-B2 | Method for the preparation of atorvastatin and intermediates used therein | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2012-05-15 | — | — | US | disclosed |
| US-20110015407-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2011-01-20 | — | — | US | disclosed |
| EP-2245008-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | Chong Kun Dang Pharmaceutical Corp. (KR) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009093776-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2009-07-30 | — | — | WO | disclosed |
| WO-2006110918-A1 | PYRROLE COMPOUNDS AND USES THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368256-A1 | NEW BICYCLICPYRIDINE DERIVATIVES | CACNA1E, CHRM1, CHRM2 | MEN1 906/4885KMT2A 1883/4885MAPT 2019/4885 |
| US-20110015407-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | HMGCR, PCSK9, CETP | MEN1 2601/4885KMT2A 3769/4885MAPT 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.